Abstract
In patients with neurodegenerative disorders, namely Alzheimer’s disease and Huntington’s disease, we compared serum concentrations of tryptophan, kynurenine and the kynurenine per tryptophan ratio with concentrations of soluble immune activation markers. Significantly lower tryptophan concentrations were observed in the patients, and lower tryptophan levels as well as higher kynurenine levels and higher kynurenine per tryptophan ratios correlated with higher concentrations of neopterin, and soluble receptors for TNF and interleukin-2. In both groups of patients tryptophan concentrations correlated inversely with the degree of mental retardation. No such association existed for the duration of the disease. The data show that systemic chronic immune activation in patients with Alzheimer’s disease and Huntingtons disease is associated with significant degradation of tryptophan, which is most likely due to activation of indoleamine (2,3)-dioxygenase by immunologic stimuli. Further studies will be necessary to investigate a potential role of tryptophan degradation in the pathogenesis of neurodegenerative disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aisen, P.S. and Davis, K.L., 1994, Inflammatory mechanisms in Alzheimer’s disease: implications for therapy, Am. J. Psych. 151:1105–1113.
Beal, M.F., 1995, Aging, energy, and oxidative stress in neurodegenerative diseases, Ann. Neurol. 38:357–366.
Blass, J.B., 1993, Pathophysiology of the Alzheimer’s syndrome, Neurology 43(Suppl 4), 25–38.
Diez-Ruiz, A, Tilz, G.P., Zangerle, R., Baier-Bitterlich, G., Wachter, H., and Fuchs, D., 1995, Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis, Eur. J. Haematol. 54:1–8.
Freese, A., Swartz, K.J., During, M.J., and Martin, J.B., 1990, Kynurenine metabolites of tryptophan: Implications for neurological diseases, Neurology 40:691–695.
Fuchs, D., Malkowsky, M, Reibnegger, G., Forni, G., and Wachter, H., 1989/90, Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol. Lett. 23:103–108.
Fuchs, D., Möller, A.A., Reibnegger, G., Stöckle, E., Werner, E.R., and Wachter H., 1990, Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 3:873–876.
Fuchs, D., Weiss, G., and Wachter, H., 1993, Neopterin, biochemistry and clinical use as a marker for cellular immune reactions, Int. Arch. Allergy Immunol. 101:1–6.
Gasse, T., Widner, B., Baier-Bitterlich, G., Sperner-Unterweger, B., Leblhuber, B., Wachter, H., and Fuchs, D., 1998, Abnormal tryptophan metabolism, neurologic/psychiatric disturbances and its relationship to immune activation, in: Progress in HPLC-HPCE: Vol. 7. Neurochemical markers of degenerative diseases and drug addiction, (G.A. Qureshi, H. Parvez, P. Caudy, and S. Parvez, eds), pp. 351–381, VSP Püress, Zeit.
Hagberg, L., Dotevall, L., Norkrans, G., Larsson, M., Wachter, H., and Fuchs, D., 1993, Cerebrospinal fluid neopterin concentrations in central nervous system infection. J. Infect. Dis. 168:1285–1288.
Hampel, H., Muller-Spahn, F, Berger, C., Haberl, A., Ackenheil, M., and Hoch, C., 1995, Evidence of blood-cerebrospinal fluid impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation, Dementia 6:348–354.
Heyes, M.P., Saito, K., Crowley, J.S., Davies, L.E., Demitrack, M.A., Dez, M., Diling, L.A., Elia, J., Kruesi, M.J., and Lackner, A., 1992, Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease, Brain 115:1249–1273.
Jenner, P., 1994, Oxidative damage in neurodegenerative disease, Lancet 344:796–798.
Leblhuber, F., Walli, J., Tilz, G.P., Jellinger, K., Wachter, H., and Fuchs, D., 1996, Increased serum neopterin concentrations in a patient with Creutzfeld-Jacob disease, J. Neurol. Neurosurg. Psych. 10:138–139.
Leblhuber, F., Walli, J., Jellinger, K., Tilz, G.P., Widner, B., Laccone, F., and Fuchs, D., 1998, Activated immune system in patients with Huntington’s disease, Clin. Chem. Lab. Immunol. 36:747–740.
Leblhuber, F., Walli, J., Tilz, G.P., Demel, U., Widner, B., and Fuchs, D., Activated immune system in patients with Alzheimer’s disease, Clin. Chem. Lab. Immunol. (in press).
Martin, J.B., 1984, Huntington’s disease: new approaches to an old problem. Neurology 34:1059–1072.
Rich, B.J., Rasmusson, D.X., Folstein, N.F., Carson, R.A., Kawas, C., and Brandt, J., 1995, Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease, Neurology 45:51–55.
Rogers, J., Webster, S., Lue, L.F., Brachova, L., Civin, W.H., Emmerling, M., Shivers, B., Walker, D., and McGeer, P., 1996, Inflammation and Alzheimer’s disease pathogenesis. Neurobiol. Ageing 17:681–686.
Schwarcz, R., Tamminga, C.A., Kurlan, R., and Shoulson, I., 1988, Cerebrospinal fluid levels of quinolinic acid in Huntington’s disease and Schizophrenia. Ann. Neurol. 24:580–582.
Shahabuddin, S., 1991, Expression and release of IL-2 receptor and production of IL-2 by activated T-lymphocyte subsets, J. Clin. Lab. Immunol. 36:27–32.
Shalit, F, Sredni, B., Brodie, C., Kott, E., and Huberman, M.T., 1995, Lymphocyte subpopulations and activation markers correlate with severity of Alzheimer’s disease, Clin. Immunol. Immunopathol. 75:246–250.
Singh, V.K., 1996, Immune activation model in Alzheimer disease, Mol. Chem. Neuropathol. 28:105–111.
Singh, V.K., 1997, Neuroautoimmunity: pathogenic implications for Alzheimer’s disease, Gerontology 43:79–94.
Widner, B., Werner, E.R., Schennach, H., Wachter, H., and Fuchs, D., 1997, Simultaneous measurement of serum tryptophan and kynurenine by HPLC, Clin. Chem. 43:2424–2426.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Widner, B., Leblhuber, F., Walli, J., Tilz, G.P., Demel, U., Fuchs, D. (1999). Degradation of Tryptophan in Neurodegenerative Disorders. In: Huether, G., Kochen, W., Simat, T.J., Steinhart, H. (eds) Tryptophan, Serotonin, and Melatonin. Advances in Experimental Medicine and Biology, vol 467. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4709-9_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4709-9_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7133-5
Online ISBN: 978-1-4615-4709-9
eBook Packages: Springer Book Archive